Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
HSHS Saint Nicholas Hospital
mi
from
Sheboygan, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
HSHS Saint Nicholas Hospital
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Aspirus UW Cancer Center
mi
from
Wisconsin Rapids, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Aspirus UW Cancer Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Hawaii Oncology Inc-Pali Momi
mi
from
'Aiea, HI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Hawaii Oncology Inc-Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Pali Momi Medical Center
mi
from
'Aiea, HI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Pali Momi Medical Center
mi
from
'Aiea, HI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Memorial Sloan-Kettering Cancer Center West Harrison
mi
from
Harrison, NY
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Memorial Sloan-Kettering Cancer Center West Harrison
mi
from
Harrison, NY
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Novant Health Oncology Specialists-Statesville
mi
from
Statesville, NC
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Novant Health Oncology Specialists-Statesville
mi
from
Statesville, NC
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients
Status: Enrolling
Updated:  4/6/2018
UCSF Imaging Center at China Basin
mi
from
San Francisco, CA
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients
Status: Enrolling
Updated: 4/6/2018
UCSF Imaging Center at China Basin
mi
from
San Francisco, CA
Click here to add this to my saved trials
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Johns Hopkins University
mi
from
Baltimore, MD
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/9/2018
Johns Hopkins University
mi
from
Baltimore, MD
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/9/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/9/2018
Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/9/2018
Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/9/2018
Oregon Health and Science University
mi
from
Portland, OR
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/9/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/9/2018
Univ of Washington
mi
from
Seattle, WA
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/9/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer
A Phase II Study of Ipilimumab PLUS Androgen Deprivation Therapy in Castrate Sensitive Prostate Carcinoma
Status: Enrolling
Updated:  4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer
A Phase II Study of Ipilimumab PLUS Androgen Deprivation Therapy in Castrate Sensitive Prostate Carcinoma
Status: Enrolling
Updated: 4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated:  4/11/2018
Northwestern University
mi
from
Chicago, IL
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated: 4/11/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated:  4/11/2018
Veterans Affairs Medical Center - Lakeside Chicago
mi
from
Chicago, IL
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated: 4/11/2018
Veterans Affairs Medical Center - Lakeside Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated:  4/11/2018
John H Stroger Hospital of Cook County
mi
from
Chicago, IL
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated: 4/11/2018
John H Stroger Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men
Status: Enrolling
Updated:  4/11/2018
University of Connecticut Health Center
mi
from
Farmington, CT
Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men
Status: Enrolling
Updated: 4/11/2018
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer
Phase II Study to Evaluate the Efficacy of Intensity Modulated Radiation Therapy With Hypofractionated Radiosurgical Boosts in the Treatment of Clinically Localized Prostate Cancer
Status: Enrolling
Updated:  4/12/2018
MedStar Georgetown University Hospital
mi
from
Washington,
Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer
Phase II Study to Evaluate the Efficacy of Intensity Modulated Radiation Therapy With Hypofractionated Radiosurgical Boosts in the Treatment of Clinically Localized Prostate Cancer
Status: Enrolling
Updated: 4/12/2018
MedStar Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Focal Therapy for Prostate Cancer
Focal Therapy for the Treatment of Organ Confined Prostate Cancer
Status: Enrolling
Updated:  4/17/2018
University of Maryland School of Medicine
mi
from
Baltimore, MD
Focal Therapy for Prostate Cancer
Focal Therapy for the Treatment of Organ Confined Prostate Cancer
Status: Enrolling
Updated: 4/17/2018
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer
PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER
Status: Enrolling
Updated:  4/18/2018
Sharp Healthcare
mi
from
San Diego, CA
Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer
PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER
Status: Enrolling
Updated: 4/18/2018
Sharp Healthcare
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated:  4/18/2018
Site US10003
mi
from
Evanston, IL
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated: 4/18/2018
Site US10003
mi
from
Evanston, IL
Click here to add this to my saved trials
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated:  4/18/2018
Site US10054
mi
from
Worcester, MA
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated: 4/18/2018
Site US10054
mi
from
Worcester, MA
Click here to add this to my saved trials
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated:  4/18/2018
Site US10047
mi
from
New York, NY
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated: 4/18/2018
Site US10047
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated:  4/18/2018
Site US10014
mi
from
Charleston, SC
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated: 4/18/2018
Site US10014
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated:  4/18/2018
Site US10012
mi
from
Myrtle Beach, SC
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Status: Enrolling
Updated: 4/18/2018
Site US10012
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study
Status: Enrolling
Updated:  4/20/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study
Status: Enrolling
Updated: 4/20/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Status: Enrolling
Updated:  4/23/2018
Yale Cancer Center
mi
from
New Haven, CT
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Status: Enrolling
Updated: 4/23/2018
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Status: Enrolling
Updated:  4/23/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Status: Enrolling
Updated: 4/23/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
University of Alabama Hematology Oncology Clinic at Medical West
mi
from
Birmingham, AL
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
University of Alabama Hematology Oncology Clinic at Medical West
mi
from
Birmingham, AL
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
IU Health Central Indiana Cancer Centers
mi
from
Indianapolis, IN
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
IU Health Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Metro Health Cancer Care
mi
from
Wyoming, MI
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Metro Health Cancer Care
mi
from
Wyoming, MI
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Nebraska Cancer Specialists
mi
from
Omaha, NE
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center
mi
from
New York, NY
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
MUSC Hollings Cancer Center
mi
from
Charleston, SC
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
MUSC Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
University of Texas Medical Branch
mi
from
Galveston, TX
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Status: Enrolling
Updated:  4/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Status: Enrolling
Updated: 4/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials